Platform WatchJuly 4, 2026via The Decoder
Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable
Why it matters
Anthropic is expanding beyond AI infrastructure into vertical application (drug discovery), signaling how AI labs are capturing end-to-end value chains and competing in adjacent industries. This represents a strategic shift from model-as-a-service to applied outcomes-driven deployment.
Key signals
- Anthropic launches proprietary drug discovery program
- Focus: neglected diseases Big Pharma deems unprofitable
- Novartis CEO estimate: AI could reduce development timeline from 12 years to 7-8 years
- Novartis CEO estimate: AI could increase success rate from 8% to 16%
- Published July 4, 2026
The hook
Anthropic just became a drug company. Not a partner—a builder. Neglected diseases that Big Pharma won't touch.
Anthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time from twelve years to seven or eight and double the success rate from 8 to 16 percent.